Program
taletrectinib
Also written as “Taletrectinib”, “AB-106” and “DS6051b”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasms, led by 2 companies.
Drug pageTaletrectinib: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Nuvation Bioits history only | 105 open or running | phase 3since Aug 12, 2024 | Oct 15, 2014 | Feb 2, 2027phase 1 · NCT07742384 |
| Daiichi Sankyo | 10 open or running | phase 1since Feb 2, 2016 | Feb 2, 2016 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Daiichi Sankyo only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Feb 2, 2016First study: phase 1 study in Advanced Solid Malignant TumorsFirst studyNCT02675491 · 15 enrolled · Japan
- Jun 9, 2020Named taletrectinibINNProposed as its International Nonproprietary Name in WHO's List 123 · before, AB-106
TargetBeta
“An orally available inhibitor of the receptor tyrosine kinases C-ros oncogene 1 (ROS1) and the neurotrophic tyrosine receptor kinase (NTRK) types 1, 2 and 3, ”NCIt, by rule
“Proto-oncogene tyrosine-protein kinase ROS inhibitor; Neurotrophic tyrosine kinase receptor inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| repotrectinibrule | Bristol-Myers Squibb | phase 3 | 9 |
Studies
The one study Daiichi Sankyo leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02675491Advanced Solid Malignant Tumors · Japan | 1 | Completed | Dec 27, 2021 | 15 |
How it is read
Names in the registry
- “Taletrectinib”, 5 entries
- “AB-106”, 2 entries
- “DS6051b”, 1 entry
- “DS-6051b”, 1 entry
- “AB-106, Itraconazole”, 1 entry
Codes read as this program: AB106.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.